1P-LSD vs LSD
A side-by-side research comparison of 1P-LSD and LSD across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 1P-LSD | LSD |
|---|---|---|
| Full name | 1-Propionyl-LSD | Lysergic acid diethylamide |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (research compound) | Schedule I (research compound) |
| Mechanism | Likely acts as a prodrug for LSD, activating serotonin 5-HT2A receptors. | Activates serotonin 5-HT2A receptors (and others), changing perception, mood and the way brain networks communicate. Effects last much longer than most psychedelics. |
| Molecular weight | 379.50 g/mol | 323.43 g/mol |
| Half-life | ~3-5 hours | ~3-5 hours |
| Bioavailability | Oral | Oral |
| Typical dose | Varies by individual and setting | 100-200 mcg in clinical trials |
| Frequency | Occasional | One to a few supervised sessions |
| Route | Oral | Oral, in a supervised therapeutic setting |
1P-LSD reported benefits
- Nearly identical to LSD
- Used as a research LSD analog
- Long, classic psychedelic experience
- Well-known harm-reduction profile
LSD reported benefits
- Studied for anxiety in serious illness
- Explored for depression and addiction
- Long duration allows deep therapeutic work
- Renewed clinical research interest
Related comparisons
Research and educational reference only. Not medical advice.